Jatin Shah - Feb 17, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Medical Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Jatin Shah
Stock symbol
KPTI
Transactions as of
Feb 17, 2022
Transactions value $
-$15,833
Form type
4
Date filed
2/22/2022, 03:19 PM
Previous filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$15.8K -1.31K -1% $12.12* 129K Feb 17, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.